Abstract:While an increased incidence of thromboembolic events and hypercoagulability during acute SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection has been well described,[1] [2] arterial thrombosis post COVID-19 (coronavirus disease 2019), although uncommon, has yet to be recognized as part of the late sequelae of COVID-19 (i.e., "long COVID") by the Centers for Disease Control and Prevention (CDC) in their guidance of "Late Sequelae of COVID-19" under the Clinical Care Guidance for Healthcare Professionals about Coronavirus (COVID-19),[3] or by the National Institute for Health and Care Excellence (NICE) in recently published living guidelines on post–acute COVID-19.[4] This is, despite the emerging reports of post COVID-19 arterial thrombosis, particularly in patients without cardiovascular risk factors.[5] [6] [7] [8] [9] In a preprint study[10] evaluating the incidence of neurological and psychiatric sequelae in 6 months in 236,379 post COVID-19 survivors, the authors noted an increased risk of cerebrovascular events, with higher hazard ratio in most diagnostic categories than after influenza or other respiratory infections. A high incidence of stroke was found, as high as 1:10 (or 3% in patients with first episode of stroke) in patients who had previously experienced delirium or altered mental state. Moreover, it was noted that the incidence of these complications was increased even in individuals who had not required hospitalization. In a case series on delayed arterial thrombosis post COVID-19,[5] we described four cases in young males (aged <40 years) with previous asymptomatic SARS-CoV-2 infection, and lack of preexisting cardiovascular risk factors. These patients presented with a median of 78 days from positive SARS-CoV-2 total antibody positivity to thrombotic event with catastrophic strokes, acute myocardial infarction, and acute ischemic limb. Standard thrombophilia workup (including tests for antiphospholipid syndrome, protein C, protein S, antithrombin levels, and factor V Leiden mutation) was negative, with von Willebrand factor (VWF) and D-dimer levels remaining persistently elevated weeks after their initial thrombotic event. Our observations suggest that the SARS-CoV-2 virus poses significant chronic immuno-thrombogenicity which may cumulate eventually in a major thrombotic event that occurs unexpectedly many weeks later in fit patients with mild or asymptomatic COVID-19 infection. Sustained prothrombotic changes in COVID-19 patients were found in a separate study,[11] with increased thrombin generation, decreased plasma fibrinolysis, elevated factor VIII, VWF, and plasminogen activator inhibitor-1 (PAI-1) levels on admission and 4 months after discharge, suggestive of platelet activation and ongoing intravascular coagulation. Several other case reports highlight the phenomena of post COVID-19 arterial events as well. Notably, two case reports demonstrated the development of late, lower extremity, multilevel arterial thrombosis in a 24-year-old male and a 54-year-old male, both with nonsevere COVID-19 and without previous significant medical histories.[6] [7] A previously healthy 61-year-old female with COVID-19 not requiring hospitalization presented 32 days later with fatal main pulmonary artery thrombosis discovered on autopsy.[8] Although pulmonary artery thrombosis is often considered a form of venous thrombosis, as the occlusion can result from emboli arising from a deep vein thrombosis, we make a point here that (1) this will still terminate in the pulmonary arteries and not pulmonary veins and (2) that in COVID-19, pulmonary thromboses are thought to originate in the pulmonary arteries/vasculature.[12] Also, a 35-year-old male with a medical history of mild-intermittent asthma and obesity presented 49 days after the onset of flu-like illness not requiring hospitalization (SARS-CoV-2 antibodies were positive on day 2 of admission) with extensive thrombosis including a large left ventricle thrombus, right coronary artery thrombosis, and a middle cerebral artery thrombosis.[9] In summary, these post COVID-19 cases, most of who were young and with no evident cardiovascular risk factors, developed delayed, massive arterial thromboses.Although post thrombotic events are known to occur after acute viral infections such as influenza,[13] [14] where up to a third of acute myocardial infar -Abstract Truncated-

Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales

Impact of vaccination on the association of COVID-19 with cardiovascular diseases: An OpenSAFELY cohort study

A Nationwide Cohort Study Assessing One-Year Cardiovascular and Thromboembolic Risks After Severe COVID-19 Compared to Matched Controls

Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank

The Risk of Thrombosis after Acute-Covid-19 Infection

Predictors and mortality risk of venous thromboembolism in patients with COVID-19: systematic review and meta-analysis of observational studies

Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19

Post COVID-19 Arterial Thromboembolism: A Clear and Present Danger

Risk of Cardiovascular Events After COVID-19

Persistent increase of cardiovascular and cerebrovascular events in COVID-19 patients: a 3-year population-based analysis

Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19

Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England

Risk of major adverse cardiovascular events after SARS-CoV-2 infection in British Columbia: a population-based study

The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications

Association of COVID-19 and influenza vaccinations and cardiovascular drugs with hospitalisation and mortality in COVID-19 and Long COVID: 2-year follow-up of 17 million individuals in England

Vascular Manifestations of COVID-19 – Thromboembolism and Microvascular Dysfunction

Genetic risk, adherence to healthy lifestyle and acute cardiovascular and thromboembolic complications following SARS-COV-2 infection

Estimating the Effect of Coronavirus Disease 2019 (COVID-19) Vaccination and Infection Variant on Post-COVID-19 Venous Thrombosis or Embolism Risk

Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry

Adjudicated cardiovascular events in a cotemporary multicenter cohort of patients with COVID-19: findings from the CORONA-VTE Registry